Cobimetinib

From Wikipedia, the free encyclopedia
  (Redirected from XL518)
Jump to: navigation, search
Cobimetinib
Cobimetinib.svg
Systematic (IUPAC) name
[3,4-Difluoro-2-(2-fluoro-4-iodoanilino)phenyl]{3-hydroxy-3-[(2S)-piperidin-2-yl]azetidin-1-yl} methanone
Clinical data
  • Investigational
Identifiers
934660-93-2
None
PubChem CID 16222096
ChemSpider 17349374
ChEMBL CHEMBL2146883
Chemical data
Formula C21H21F3IN3O2
531.3 g/mol

Cobimetinib (GDC-0973, XL-518) is a MEK inhibitor being developed by Exelixis and Roche. It is being studied in combination with vemurafenib to treat several cancers, including melanoma. One trial should complete in 2017.[1] After good results in 2014 the combination has been submitted to EC and FDA for marketing approval.[2]

References[edit]

External links[edit]